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A B S T R A C T
Background: Despite the fact that rare cancer is a new target of cancer control in Japan, the incidence of
rare cancers is unknown and there is no generally accepted deﬁnition of rare cancers in this country.
With the aim of calculating incidences of rare cancers in Japan, we therefore adopted a deﬁnition and
classiﬁcation of rare cancers that had been published in the European Union (EU) in 2011.
Methods: Using incidence data between 1998 and 2007 submitted by 12 of population based cancer
registries in Japan that met our quality criteria and drawing on the EU deﬁnition (incidence <6 per
100,000 per year), we estimated the incidences of 845 combinations of tumor sites and histological
groups and thus identiﬁed the cancers that are rare in Japan.
Results: After identifying 193 combinations of tumor sites and histological groups that ﬁt our criteria for
rare cancers, we estimated their incidence to be about 75 per 100,000, which corresponds to about
94,800 new diagnoses in 2012 or approximately 15% of all cancer diagnoses. The categorization of rare
and common cancers was almost the same in Japan as in EU.
Conclusions: The present study provides an indication of the size of the rare cancer burden in Japan and
epidemiological information to explore this. We are expecting further discussion based on our results
with stakeholders in order to construct a Japanese deﬁnition of rare cancers.
 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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jou r nal h o mep age: w ww.c an cer ep idem io log y.n et1. Introduction
Rare cancers were mentioned for the ﬁrst time in ofﬁcial
documents in Japan in the 2012 revision of ‘‘The Basic Plan to
Promote Cancer Control’’, which is based on the Cancer Control Act.
Because some patient advocacy groups believe that patients with
rare cancers receive less medical resources and information than
patients with more common cancers, they have requested that
more attention be paid to rare cancers with a view to improving
management of these patients. Although the medical term ‘‘rare* Corresponding author. Tel.: +81 6 6879 2526; fax: +81 6 6879 2524.
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3.0/).cancers’’ is commonly used, we could ﬁnd no deﬁnition of rare
cancers in Japan. The authors believe that there are three basic
considerations that underpin the deﬁnition of rare cancers. The
ﬁrst is the choice of the best indicator for evaluating rarity. The
second is the categorization of cancers deﬁned by a combination of
numerous cancer sites and histological types. The last is deciding
on the threshold for rarity.
We found two generally accepted deﬁnitions of rare cancers in
publications from other countries. One is the consensus produced
in the European Union (EU) in 2011 by the research project named
RARECARE [1], and the other the consensus of a workshop in 2007
sponsored by the National Cancer Institute in the United States
(US) [2].
In Europe, rare diseases were deﬁned in the 1990s as those with
a prevalence of <50 per 100,000; the same criterion is also often
used for rare cancers [3]. However, prevalence is not an
appropriate measure of disease frequency for conditions like
cancer that have a sub-acute clinical course. Therefore, the
RARECARE study group, an international consensus group fundede under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
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European Commission, agreed on incidence as the most appropri-
ate indicator for measuring the frequency of rare cancers [1].
The incidence of a cancer clearly depends on how that entity is
categorized. Standard cancer surveillance summaries typically
classify more common cancers by their major anatomic sites or by
histologically-deﬁned diagnostic groups. Greenlee et al. [2]
reported the incidence of rare and non-rare cancers in US by site
and histologic grouping. After extensive discussion with stake-
holders comprising oncologists, pathologists, cancer epidemiolo-
gists, and patients advocacy groups, the RARECARE study group
produced a new type of list of cancers; this list is in three
hierarchical layers and takes into account ‘‘families of tumors’’ and
‘‘tumors that are clinically meaningful’’ [1].
Furthermore, an optimal threshold of rarity would depend on
both a classiﬁcation of cancer and the social and relative burden of
the diseases of interest at that time. According to the EU deﬁnition,
rare cancers have an annual incidence of less than 6 per 100,000
[1], whereas according to the US deﬁnition the required incidence
is less than 15 per 100,000 [2].
After reviewing the studies cited above, we concluded that the
strategy of the RARECARE study group for achieving consensus on
the deﬁnition of rare cancers was sound and therefore decided to
adapt the RARECARE deﬁnition to assess the burden of rare cancer
in Japan.
In the hope that this data will be useful for study and research of
rare cancers, we have determined the incidence of rare cancers
(annual incidence of less than 6 per 100,000) in Japan and
compared our ﬁndings with those of the RARECARE study [1].
2. Material and methods
2.1. Data sources
We obtained the Monitoring of Cancer Incidence in Japan (MCIJ)
1993–2007 research data ﬁle, based on the September 2011 data
submitted by 33 population-based cancer registries (CRs) in Japan
[4]. For the present study, we limited cases to invasive cancer
diagnosed in the latest 10 years (i.e. 1998–2007), and applied
exclusion criteria for comparability and quality of data in Cancer
Incidence in Five Continents, Volume IX as following; data with
more than 20% of death-certiﬁcate-only (DCO) cases, ill-deﬁned
site cases, age-unknown cases and an overall the percentage of
microscopically veriﬁed cases (MV%) less than 75%. [5]. However,
we could not evaluate the percentage of age-unknown cases,
because the MCIJ data ﬁle did not include such cases. The term
‘‘cancer’’ refers to any invasive malignancy, regardless of site or
histologic type.
2.2. List of cancers
The present analysis was based on a list of cancer entities
produced by the RARECARE study group. We obtained a
spreadsheet named ‘‘Rare_Cancers_list_March2011’’ which in-
cluded information on all cancers deﬁned by the RARECARE
project through the website [6]. This list is hierarchically organized
into three layers based on various combinations of the third edition
of the International Classiﬁcation of Diseases for Oncology (ICD-O-
3) morphology and topography codes [7]. The ﬁrst layer comprises
59 cancer entities. All cancer entities categorized as ﬁrst layer are
considered to involve the same clinical expertise and patient
referral structure. Each ﬁrst layer entity is split into varying
numbers of second layers, of which there are 197 entities; all
second layer entities are considered to require similar clinical
management and research. Each second layer entity is further
divided into varying numbers of third layers; these correspond tothe World Health Organization names of individual cancer entities
and their corresponding ICD-O-3 codes. There are 587 cancer
entities in the third layer.
In our Japanese version, we added two cancer entities
(morphology code 8700; pheochromocytoma, malignant and
morphology code 8710-8711; Glomus tumor, malignant) to the
second layer under the ﬁrst layer of neuroendocrine tumors and
non-glial tumors of cranial and peripheral nerves, autonomic
nervous system and paraganglia, respectively. Therefore, the
second layer comprises 197 entities in the original list, but 199
entities in our study.
2.3. Incidence
Based on the list of cancers mentioned above, we calculated
incidences of each cancer entities (total of 845) and all cancer
combined, as the number of new cases occurring in 1998–2007
divided by the total person-years in the general (male and female)
population in each CR region. The total number of new cases
occurring in 1998–2007 was approximately 632,400 from 12
selected CRs. The cumulative population covered was about 121
million, which corresponds to 10% of the population in Japan over
the period 1998–2007. We estimated the expected number of new
cases in Japan in 2012 by assuming that the incidences in all of
Japan were the same as those in our sample and multiplying the
crude incidence by the 2012 Japanese population (125,957,000).
We contrasted the incidences in Japan with those in EU which
reported by Gatta et al. [1] or published online by the RARECARE
project (‘‘Rare_Cancers_list_March2011’’) [6].
After calculating incidences, we categorized each cancer entity
of the ﬁrst or second layer into rare or common based on the
RARECARE deﬁnition (incidence <6/100,000/year is rare) the same
as the RARECARE study [1].
2.4. Data quality indicators
We calculated the proportion of DCO cases and MV cases among
our subject data. In addition, the following two other data quality
indicators were calculated regarding the accuracy of diagnoses and
completeness of incidence for rare cancers; the proportion of cases
with not-otherwise-speciﬁed (NOS) morphology (M) codes (ICD-
O-3 M8000 and 8001) and the cases with poorly deﬁned
topography (codes C260, C268, C269, C390, C398, C399, C559,
C579, C639, C689, C729, C759–765, C767–768).
3. Results
An excerpt of our result regarding incidences for 845 cancer
entities in total and the corresponding incidences in EU [6] is
shown in Table 1, as a part of online data for information to help
understanding structure of the cancer list. Additional data may be
found in the online version of this article (Table A).
In Japan there were 16 entities with incidence >6/100,000/year
(common cancers) and in EU 19 such entities. Conversely, in Japan
there were 193 entities with incidence under 6/100,000/year (rare
cancers) and in EU 186 such entities. Of the 16 common cancer
entities in Japan, four entities were not common in EU, and ﬁve
cancer entities were common in EU but rare in Japan (Table 2).
About 514 persons per 100,000 were diagnosed with cancer in
Japan each year between 1998 and 2007: this translates to 647,300
new cancer cases in 2012. The annual incidence of all rare cancers
in Japan was about 75 per 100,000 between 1998 and 2007: this
translates to about 94,800 new diagnoses in 2012.
Table 3 shows the incidences of rare and common cancers by
summary sites in comparison between Japan and EU [1]. Although
the statistics in the article by Gatta et al. [1] and those in the list
Table 1
Incidence rates in Japan and EU27 by the cancer list of the RARECAREa study (Excerpt). Source: EU27 (1998–2002) [6].
Rare (R) or
common (C)b
Layer Entitie of tumor Crude rate per 100,000
Japan EU27
1 Epithelial tumors of nasal cavity and sinuses 0.86 0.44
R 2 Squamous cell carcinoma with variants of nasal cavity and sinuses 0.63 0.31
3 Squamous carcinoma 0.59 0.24
3 Verrucous carcinoma 0.00 <0.01
3 Squamous cell carcinoma spindle cell 0.01 <0.01
3 Papillary squamous cell carcinoma 0.00 <0.01
3 Adenosquamous carcinoma 0.00 <0.01
3 Squamous cell carcinoma, adenoid 0.00 <0.01
3 Basaloid squamous cell carcinoma 0.00 <0.01
R 2 Lymphoepithelial carcinoma of nasal cavity and sinuses 0.00 <0.01
R 2 Undifferentiated carcinoma of nasal cavity and sinuses 0.03 0.02
R 2 Intestinal type adenocarcinoma of nasal cavity and sinuses 0.00 <0.01
1 Epithelial tumors of nasopharynx 0.45 0.44
R 2 Squamous cell carcinoma with variants of nasopharynx 0.36 0.33
3 Squamous carcinoma 0.23 0.16
3 Squamous cell carcinoma nonkeratinizing, NOS 0.02 0.02
3 Squamous cell carcinoma keratinizing, NOS 0.00 0.02
3 Papillary squamous cell carcinoma 0.00 <0.01
3 Basaloid squamous cell carcinoma 0.00 NE
3 Squamous cell carcinoma, adenoid 0.00 <0.01
3 Lymphoepithelial carcinoma 0.05 0.06
3 Undifferentiated carcinoma 0.05 0.06
R 2 Papillary adenocarcinoma of nasopharynx 0.00 <0.01
1 Epithelial tumors of major salivary glands and salivary-gland type tumors 1.04 1.31
R 2 Epithelial tumors of major salivary glands 0.66 0.73
3 Squamous carcinoma 0.07 0.12
3 Large cell carcinoma 0.00 0.01
3 Lymphoepithelial carcinoma 0.00 <0.01
3 Carcinosarcoma, NOS 0.00 <0.01
3 Adenocarcinoma NOS 0.12 0.14
3 Clear cell adenocarcinoma, NOS 0.00 <0.01
3 Mucinous adenocarcinoma 0.01 <0.01
3 Ductal carcinoma 0.04 0.01
3 Oxyphilic adenocarcinoma 0.01 <0.01
3 Papillary cystadenocarcinoma, NOS 0.00 <0.01
3 Adenoid cystic carcinoma 0.13 0.12
3 Mucoepidermoid carcinoma 0.12 0.12
3 Acinic cell adenocarcinoma 0.06 0.09
3 Malignant myoepithelioma 0.01 <0.01
3 Carcinoma in pleomorphic adenoma 0.03 0.02
Omitted below
a RARECARE: The project Surveillance of Rare Cancers in Europa.
b Rare or Common: Rare cancer < 6/100,000 and Common cancer  6/100,000.
Table 2
The differences of common or rare categorization between Japan and EU27. Source:
EU27 (1998–2002) [6].
Entitie of tumor Incidence
rate per
100,000
in Japan
Incidence
rate per
100,000
in EU27
Common in Japan and Rare in EU27
Squamous cell carcinoma with variants
of oesophagus
10.58 3.40
Hepatocellular carcinoma of Liver and IBT 23.66 3.09
Adenocarcinoma with variants of
gallbladder and EBT
7.5 2.62
Carcinomas of thyroid gland 8.16 3.65
Rare in Japan and Common in EU27
Invasive lobular carcinoma of breast 1.05 7.18
Adenocarcinoma with variants of corpus uteri 4.98 9.53
Malignant skin melanoma 0.93 12.41
Basal cell carcinoma of skin 3.34 32.05
Squamous cell carcinoma with variants of skin 2.87 16.39
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March2011’’) [6] seemed to be different regarding the hematopoi-
etic system, we referred to the article version the same as the other
sites. The proportion of rare and common cancers does not add upto 100% for each cancer site, because some cancers could not be
classiﬁed as either rare or common cancer entities because
information about their morphology was not available. Therefore,
the proportion of cancers not classiﬁed as any rare or common
cancer entity is shown as ‘‘other’’. The incidence of rare cancers was
15% of that of all cancers in Japan, which is 7% less than that in EU.
The proportion of the ‘‘other’’ category varied with site, being
highest for respiratory cancers (27%) and lowest for skin cancers
(0%). For all sites, this category was 20% for Japan and 19% for EU;
the proportions in the two regions were similar by site except for
the hematopoietic system (Japan 17%, EU 6%).
Fig. 1 shows age-speciﬁc incidences by age group for rare and
common cancers. Rare cancers predominated in persons aged up to
34 years whereas from age 35 years plus, the common cancers
became increasingly prominent.
Fig. 2 shows the distribution of number of cancer entities (a)
and estimated number of new cancer diagnoses in each year
according to incidence (b). About 81% of rare cancers had an annual
incidence of under 0.5 per 100,000. These ‘‘very rare cancers’’,
which included most types of rare cancers, accounted for only
16,700 (2.6%) of the 647,300 new cancers diagnosed in each year.
Another 17 rare cancer entities with an incidence of 0.5–1 per
100,000 accounted for 15,700 cases (2.4%), whereas the 20 cancer
entities with incidence 1–6 per 100,000 accounted for 62,400 cases
Table 3
Incidence and distribution for rare and common cancers by summary site in Japan and EU27. Source: EU27 (1998–2002) [1].
Rare or common Summary sites Crude incidence per
100,000 per year
Incidence distribution
(%)
Estimated incidence
cases in Japan per year
Japan EU27 Japan EU27
Rare Digestive tract 6.7 17.5 3 15 8,414
Common Digestive tract 198.5 75.3 77 67 250,012
Other Digestive tract NA NA 20 18 NA
All Digestive tract 259.3 113.7 100 100 326,556
Rare Respiratory tract 6.9 13.6 10 21 8,729
Common Respiratory tract 45.3 31.5 63 49 57,109
Other Respiratory tract NA NA 27 30 NA
All Respiratory tract 72.0 63.9 100 100 90,714
Rare Skin 8.2 1.5 100 2 10,301
Common Skin 0.0 60.8 0 96 0
Other Skin NA NA 0 2 NA
All Skin 8.2 63.2 100 100 10,303
Rare Breast 5.1 4.4 14 7 6,404
Common Breast 24.0 47.5 65 74 34,427
Other Breast NA NA 13 19 NA
All Breast 37.0 64.1 100 100 46,647
Rare Female genital tract 16.5 16.1 86 55 20,792
Common Female genital tract 0.0 9.5 0 32 0
Other Female genital tract NA NA 14 13 NA
All Female genital tract 19.3 29.5 100 100 24,303
Rare Male genital tract 1.2 4.4 3 8 1,496
Common Male genital tract 30.3 40.6 85 78 38,122
Other Male genital tract NA NA 12 14 NA
All Male genital tract 35.8 51.9 100 100 45,064
Rare Urinary system 3.5 2.6 13 8 4,446
Common Urinary system 17.8 25.8 68 78 22,433
Other Urinary system NA NA 19 14 NA
All Urinary system 26.2 33.0 100 100 32,988
Rare Haematopoietic system 11.0 15.9 40 72 13,855
Common Haematopoietic system 12.0 4.8 43 22 15,132
Other Haematopoietic system NA NA 17 6 NA
All Haematopoietic system 27.8 22.0 100 100 34,978
Rare All sites 75.2 108.3 15 22 94,768
Common All sites 336.1 297.4 65 59 423,298
Other All sites NA NA 20 19 NA
All All sites 513.9 502.1 100 100 647,345
NA = not available.
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Fig. 1. Age-speciﬁc incidence rates per 100,000 for rare and common cancers.
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accounted for the remaining cases.
The data quality indicators regarding our study subject are
shown in Table 4. The overall proportion of DCO cases was 9.9%,
that of MV cases was 79.1% and that of ill-deﬁned site cases was
1.4%. The overall proportion of cases with ‘‘not otherwise
speciﬁed’’ morphology codes and that of cases with poorly deﬁned
topography was 16.5% and 0.3%, respectively.
4. Discussion
In this study, we comprehensively ascertained the incidence of
rare cancers by epidemiological means for the ﬁrst time in Japan.We calculated incidences for 845 cancer entities in total, and
categorized 16 common cancers and 193 rare cancers in Japan
based on the published classiﬁcation of cancers and deﬁnition of
rarity in EU [1,6]. The categorization of rare and common cancers
was almost the same in Japan as in EU. Most of the disparities in
cancer incidence pattern between Japan and EU have previously
been identiﬁed. According to previous studies [8,9], there is a
higher incidence of liver cancer, cancer of the gallbladder and
extra-hepatic biliary duct, and thyroid cancer and a lower
incidence of cancer of the body of the uterus and skin cancer in
Japan than in EU: our ﬁndings are concordant with this. Previous
studies have found that squamous cell carcinoma is the leading
morphological type of esophageal cancer in Japan [10], whereas it
is adenocarcinoma in European countries [11]. In addition, the
incidence of invasive lobular carcinoma of the breast is lower in
Asian/Paciﬁc Islander women than in non-Hispanic white women
in US [12].
Rare cancers predominantly occur in younger subjects, whereas
common cancers become increasingly prominent with increasing
age in both Japan and EU. This is not unexpected given that the
populations of Japan and EU have a relatively small proportion of
children and the risk of most cancers increases with age.
Considering that all childhood cancers are rare, it may be better
to evaluate the burden of rare cancers among adults only. In their
descriptive epidemiological study of rare cancers in US, Greenlee
et al. [2] evaluated only persons aged 20 years and older.
On the other hand, we did identify some differences between
Japan and EU in patterns of incidence of rare cancers. The
Table 4
Data quality indicators of cancers by population-based cancer registry included in
the analysis.
CR Number of
cancers
Death certiﬁcate
only (%)
Microscopic
veriﬁcation (%)
Ill-Deﬁned
Casesa (%)
CR 1 89,105 9.2 78.7 1.5
CR 2 8,416 5.0 78.1 1.1
CR 3 71,536 9.7 78.8 1.2
CR 4 11,115 15.5 76.8 1.3
CR 5 29,308 9.2 79.6 3.2
CR 6 41,762 3.7 79.3 1.0
CR 7 121,425 16.7 77.4 1.7
CR 8 11,686 12.3 76.0 1.3
CR 9 98,827 7.5 77.7 1.3
CR 10 56,055 6.9 88.9 1.0
CR 11 5,098 6.2 75.8 1.5
CR 12 88,089 8.6 81.8 1.1
All CRs 632,422 9.9 79.1 1.4
a Ill-deﬁned: Topology code C26-, C39-, C48-, C76-, C80 CR = cancer registry.
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whole than in EU, in spite of the similar classiﬁcation of rare and
common cancers used in the two studies and the fact that the
proportion of incidence of ‘‘other’’ (not categorized as rare or
common) was almost the same in Japan as in EU. We do not believe
that these ﬁndings indicate that there is a smaller burden of rare
cancers in Japan than in EU, because the proportion of incidence of
all rare cancers or all common cancers varies depending on the
incidence of each cancer in any one category. For example, rare
cancers accounted for 3% of the incidence of all male genital system
cancers in Japan and 8% in EU (Table 3); there is one common
cancer and 10 rare cancers in this group of cancers. Thus, in Japan
the incidence of each rare cancer in the category of male genital
system cancers is lower than that in EU, which may result in lower
cumulative incidences of rare cancers in the male genital system in
Japan. In contrast, overwhelmingly high incidences of common
cancers could lead to those cancers accounting for a greater
proportion of the incidence of all common cancers. For example,
the leading cancer type in EU is ‘‘epithelial tumors of breast’’, the
incidence of which was 64 per 100,000 according to the RARECARE
study, whereas in our study the leading cancer type in Japan was
‘‘epithelial tumors of stomach’’, the incidence of which was 94 per
100,000 based on our study, about 5-fold the incidence in EU.
Furthermore, some cancers not classiﬁed as either a rare or
common cancer entity would affect the incidences of common or
rare cancers. For the hematopoietic system, in Japan the proportion
of incidence of the ‘‘other’’ category was 17%, which is 3-fold that
reported in EU. The difference of main sources of cases for
population-based cancer registries would be likely reason for the
obvious difference of the proportion of incidence of the ‘‘other’’
category for the hematopoietic system between Japan and EU.
Many population-based cancer registries in EU obtain informationfrom hematopoietic laboratories, whereas hospital reports and
death certiﬁcates are the main sources for most population-based
cancer registries in Japan [5]. Therefore, the incidences of both
common and rare cancers of the hematopoietic system in our study
would be underestimates. Although the proportion of incidence
of all rare cancers seems a simple indicator of the size of the
burden of rare cancers, it is important to recognize that it can
provide misleading information.
Our study had some limitations, one of which being that we did
not make an absolute evaluation of the various cancer incidences.
Our estimates of incidences are based on the premise that the
segments of the population covered by the selected 12 CRs are
representative of the population of Japan as a whole. Because we
deﬁned most entities of rare cancers according to a combination of
speciﬁc site and well-deﬁned histology, a combination of poorly
deﬁned site and unspeciﬁed morphology could not be consistently
classiﬁed in other way. We therefore decided to include data only
from CRs that met our quality criteria, thus excluding CRs with a
high proportion of death-certiﬁcate only cases and a low
proportion of cancers veriﬁed by microscopically. This strategy
was designed to minimize biasing and underestimating the
incidences of rare cancers. However, if we had set our inclusion
criteria too strictly, we would not have been able to ensure enough
cases to estimate the incidence of rare cancers.
To assess the representativeness of our incidences of common
cancers, we compared our data with incidences estimated for all of
Japan by the MCIJ 2006 [13]. Our incidences for major cancers
(stomach 93.8, colorectal 80.6, lung 68.2, all 513.9) were very
similar to those of MCIJ 2006 (stomach 91.5, colorectal 83.7, lung
66.9, all 520.0), suggesting that the population we studied is as
representative of the population of Japan as the population covered
by the MCIJ 2006.
In conclusion, our estimates indicate that about 94,800 (75 per
100,000 per year) new rare cancers will likely be diagnosed in
Japan annually. For the ﬁrst time, the present study provides an
indication of the size of the rare cancer burden in Japan and
epidemiological information to explore this. We are expecting
further discussion based on our results with stakeholders in order
to construct a Japanese deﬁnition of rare cancers.
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